EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression

Jianfeng Peng, Xueying Zhai, Xiaomei Liu, Zhaoqin Huang, Yimeng Wang, Peizhu Wu, Ran Gao, Xiangjiao Meng

Translational Oncology · 2025-02 · 52 · 102249

DOI: 10.1016/j.tranon.2024.102249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2025-02. Verfasst von Jianfeng Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Technology Research and Development Program of Shandong Province, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

extensive-stage small cell lung cancerimmunotherapyimmunotherapy beyond progressionsecond-line treatmentsurvival

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Shandong Provincial Key Laboratory of Pre…
  • Department of Oncology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
  • Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Förderung

  • Key Technology Research and Development Program of Shandong Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Peng, J., Zhai, X., Liu, X., Huang, Z., Wang, Y., Wu, P., Gao, R., & Meng, X. (2025). Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression. Translational Oncology, 52, 102249. https://doi.org/10.1016/j.tranon.2024.102249

Vancouver

Peng J, Zhai X, Liu X, Huang Z, Wang Y, Wu P, et al. Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression. Translational Oncology. 2025;52:102249. doi:10.1016/j.tranon.2024.102249

BibTeX
@article{Peng2025,
  author = {Peng, Jianfeng and Zhai, Xueying and Liu, Xiaomei and Huang, Zhaoqin and Wang, Yimeng and Wu, Peizhu and Gao, Ran and Meng, Xiangjiao},
  title = {Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression},
  journal = {Translational Oncology},
  year = {2025},
  volume = {52},
  pages = {102249},
  doi = {10.1016/j.tranon.2024.102249}
}
Kostenlos starten →